SMN1 and early-onset autosomal dominant Alzheimer disease: Z-FA-FMK and the analogous compound E64days, previously used as Alzheimer’s disease (AD) and brain injury treatments, rescued MN degeneration in SMA, suggesting that inhibiting protease-mediated degeneration could be a potential therapeutic for SMA (Wang et al., 2019).